Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 1999

View Archived Issues

MUC1 mucin expression related to T-cell activation

Reticulose enhances efficacy of HAART cocktail in two case studies

Amrad to distribute PathoGenesis's inhalable CF treatment in Australia

Bayer to acquire OSI's diagnostics business

Patent licensed to Endorex/Elan joint venture covers mucosal delivery systems

Preliminary phase III results disappointing for Anogesic as anal fissure therapy

Gliatech soon to begin phase II Perceptin trials in ADHD

Abbott acquires anesthesia/analgesia products from Glaxo Wellcome

Abbott and Alza update merger proceedings

Pozen licenses migraine prophylactic from Roche

AxyS and Merck extend osteoporosis collaboration

Once-weekly Fosamax as effective as daily dosing

Xenova's IND for multidrug resistance modulator gets FDA approval

Novel antitumor agents for both leukemias and solid tumors discovered by Taiwanese scientists

Calcimimetics and calcilytics designed at NPS

Sanofi-Synthelabo pipeline includes compounds with neurotrophic/neuroprotective effects

Calcium channel blockers with piperidine structure synthesized at NeuroSearch

Abbott's new LHRH antagonists, pharmaceutical compositions and use

Korean investigators disclose new hepatoprotective agents

Methylenecyclopropane nucleoside analogues as effective agents for CMV infections

Eradication of H. pylori infection obtained with low doses of new cephem

Azimilide pharmacokinetics not significantly affected by severe renal impairment

Pharmacokinetics and pharmacodynamics of eniporide assessed over wide dose range

WHI-D12 is a potent and selective inhibitor of Bruton's tyrosine kinase

New acylfulvene analogues with clinical potential identified by MGI Pharma

Geldanamycin derivative with selective activity against breast cancer developed at Sloan-Kettering

Gender does not affect PK of Sch-58235: results presented at 1999 AAPS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...